Imidazole propionate ameliorates atopic dermatitis-like skin lesions by inhibiting mitochondrial ROS and mTORC2
Authors:
Open Access
- 12 March 2024
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1324026
Abstract
Background: Imidazole propionate (IMP) is a histidine metabolite produced by some gut microorganisms in the human colon. Increased levels of IMP are associated with intestinal inflammation and the development and progression of cardiovascular disease and diabetes. However, the anti-inflammatory activity of IMP has not been investigated. This study aimed to elucidate the role of IMP in treating atopic dermatitis (AD). Methods: To understand how IMP mediates immunosuppression in AD, IMP was intraperitoneally injected into a Dermatophagoides farinae extract (DFE)/1-chloro-2,4 dinitrochlorobenzene (DNCB)-induced AD-like skin lesions mouse model. We also characterized the anti-inflammatory mechanism of IMP by inducing an AD response in keratinocytes through TNF-α/IFN-γ or IL-4 stimulation. Results: Contrary to the prevailing view that IMP is an unhealthy microbial metabolite, we found that IMP-treated AD-like skin lesions mice showed significant improvement in their clinical symptoms, including ear thickness, epidermal and dermal thickness, and IgE levels. Furthermore, IMP antagonized the expansion of myeloid (neutrophils, macrophages, eosinophils, and mast cells) and Th cells (Th1, Th2, and Th17) in mouse skin and prevented mitochondrial reactive oxygen species production by inhibiting mitochondrial energy production. Interestingly, we found that IMP inhibited AD by reducing glucose uptake in cells to suppress proinflammatory cytokines and chemokines in an AD-like in vitro model, sequentially downregulating the PI3K and mTORC2 signaling pathways centered on Akt, and upregulating DDIT4 and AMPK. Discussion: Our results suggest that IMP exerts anti-inflammatory effects through the metabolic reprogramming of skin inflammation, making it a promising therapeutic candidate for AD and related skin diseases.Keywords
This publication has 43 references indexed in Scilit:
- Metabolite interactions between host and microbiota during health and disease: Which feeds the other?Biomedicine & Pharmacotherapy, 2023
- Small molecules in the big picture of gut microbiome-host cross-talkEBioMedicine, 2022
- Microbial Imidazole Propionate Affects Responses to Metformin through p38γ-Dependent Inhibitory AMPK PhosphorylationCell Metabolism, 2020
- High glucose augments ROS generation regulates mitochondrial dysfunction and apoptosis via stress signalling cascades in keratinocytesLife Sciences, 2020
- Epidermal mammalian target of rapamycin complex 2 controls lipid synthesis and filaggrin processing in epidermal barrier formationJournal of Allergy and Clinical Immunology, 2020
- The path toward using microbial metabolites as therapiesEBioMedicine, 2019
- Microbially Produced Imidazole Propionate Impairs Insulin Signaling through mTORC1Cell, 2018
- Chrysin attenuates atopic dermatitis by suppressing inflammation of keratinocytesFood and Chemical Toxicology, 2017
- mTOR Signaling in Growth Control and DiseaseCell, 2012
- Mammalian Target of Rapamycin Protein Complex 2 Regulates Differentiation of Th1 and Th2 Cell Subsets via Distinct Signaling PathwaysImmunity, 2010